LFMD Stock Analysis: LifeMD | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 80m USD | 12M Return: -52.5% | US53216B1044 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.77M
Qual. Beats: 0
Rev. Trend: 81.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
LifeMD, Inc. is a U.S.-based direct-to-patient telehealth company that provides virtual medical care, prescriptions, and pharmacy services through several branded platforms. Its portfolio includes Rex MD, which focuses on mens health (such as erectile dysfunction, hair loss, weight loss, and insomnia); ShapiroMD, which addresses male and female hair loss with prescription and OTC products; and LifeMD PC, a virtual primary care service covering urgent, chronic, and routine care. The company also offers GLP-1-based weight management programs and in-home health monitoring devices.
The business operates on a direct-to-consumer telehealth model, allowing patients to access consultations, diagnoses, and prescription fulfillment without visiting traditional in-person providers. The company was originally founded in 1994 as Conversion Labs, Inc. and rebranded to LifeMD in February 2021. It is headquartered in New York, New York and trades on NASDAQ under the ticker LFMD.
- GLP-1 weight loss demand drives telehealth subscriber growth
- Telehealth regulation tightens scrutiny on compounded prescriptions
- Competition from Hims & Hers pressures mens health pricing
| Net Income: -21.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.30 > 1.0 |
| NWC/Revenue: -2.21% < 20% (prev -5.91%; Δ 3.70% < -1%) |
| CFO/TA -0.17 > 3% & CFO -9.91m > Net Income -21.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.8m) vs 12m ago 7.63% < -2% |
| Gross Margin: 85.91% > 18% (prev 87.57%; Δ -1.66% > 0.5%) |
| Asset Turnover: 306.4% > 50% (prev 333.6%; Δ -27.20% > 0%) |
| Interest Coverage Ratio: -36.29 > 6 (EBIT TTM -20.2m / Interest Expense TTM 555k) |
| A: -0.08 (Total Current Assets 42.1m - Total Current Liabilities 46.6m) / Total Assets 59.9m |
| B: -4.11 (Retained Earnings -246.1m / Total Assets 59.9m) |
| C: -0.30 (EBIT TTM -20.2m / Avg Total Assets 66.7m) |
| D: 0.15 (Book Value of Equity 7.97m / Total Liabilities 51.9m) |
| Altman-Z'' = -15.76 = D |
| DSRI: 1.88 (Receivables 11.5m/7.33m, Revenue 204.5m/245.4m) |
| GMI: 1.02 (GM 87.57% / 85.91%) |
| AQI: 0.81 (AQ_t 0.18 / AQ_t-1 0.23) |
| SGI: 0.83 (Revenue 204.5m / 245.4m) |
| TATA: -0.19 (NI -21.3m - CFO -9.91m) / TA 59.9m) |
| Beneish M = -2.54 (Cap -4..+1) = A |
As of November 14, 2026, the stock is trading at USD 2.20 with a total of 6,140,912 shares traded. Over the past week, the price has changed by -7.38%, over one month by -11.13%, over three months by -36.56% and over the past year by -52.49%.
Current recommended Stop Loss: 1.90 (which is 13.6% or 1.6 ATR below the current price).
LifeMD has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy LFMD.
- StrongBuy: 8
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8.1 | 269.5% |
P/E Forward = 12.8535
P/S = 0.4537
P/B = 10.752
Revenue TTM = 204.5m USD
EBIT TTM = -20.2m USD
EBITDA TTM = -11.2m USD
Long Term Debt = 5.32m USD (estimated: total debt 6.02m - short term 700k)
Short Term Debt = 700k USD (from shortTermDebt, last quarter)
Debt = 6.02m USD (from shortLongTermDebtTotal, last quarter) (leases 6.02m already included)
Net Debt = -7.97m USD (calculated: Debt 6.02m - CCE 14.0m)
Enterprise Value = 71.9m USD (79.9m + Debt 6.02m - CCE 14.0m)
Interest Coverage Ratio = -36.29 (Ebit TTM -20.2m / Interest Expense TTM 555k)
EV/FCF = 23.22x (Enterprise Value 71.9m / FCF TTM 3.10m)
FCF Yield = 4.31% (FCF TTM 3.10m / Enterprise Value 71.9m)
FCF Margin = 1.51% (FCF TTM 3.10m / Revenue TTM 204.5m)
Net Margin = -10.40% (Net Income TTM -21.3m / Revenue TTM 204.5m)
Gross Margin = 85.91% ((Revenue TTM 204.5m - Cost of Revenue TTM 28.8m) / Revenue TTM)
Gross Margin QoQ = 88.82% (prev 84.85%)
Tobins Q-Ratio = 1.20 (Enterprise Value 71.9m / Total Assets 59.9m)
Interest Expense / Debt = 9.23% (Interest Expense 555k / Debt 6.02m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -15.9m (EBIT -20.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.65 (Total Current Assets 42.1m / Total Current Liabilities 64.8m)
Debt / Equity = 0.76 (Debt 6.02m / totalStockholderEquity, last quarter 7.97m)
Debt / EBITDA = 0.71 (negative EBITDA) (Net Debt -7.97m / EBITDA -11.2m)
Debt / FCF = -2.57 (Net Debt -7.97m / FCF TTM 3.10m)
Total Stockholder Equity = 11.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.86% (Net Income -21.3m / Total Assets 59.9m)
RoE = -179.1% (Net Income TTM -21.3m / Total Stockholder Equity 11.9m)
RoCE = -117.3% (out of range, set to none) (EBIT -20.2m / Capital Employed (Equity 11.9m + L.T.Debt 5.32m))
RoIC = -423.6% (out of range, set to none) (NOPAT -15.9m / Invested Capital 3.76m)
WACC = 11.46% (E(79.9m)/V(85.9m) * Re(11.77%) + D(6.02m)/V(85.9m) * Rd(9.23%) * (1-Tc(0.21)))
Discount Rate = 11.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.51 | Cagr: 9.15%
[DCF] Terminal Value 66.76% ; FCFF base≈3.00m ; Y1≈3.23m ; Y5≈3.94m
[DCF] Fair Price = 0.98 (EV 39.3m - Net Debt -7.97m = Equity 47.3m / Shares 48.3m; r=11.46% [WACC]; 5y FCF grow 8.88% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.35 | # QB: 0
Revenue Correlation: 81.40 | Revenue CAGR: 19.71% | SUE: -0.14 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.09 | Chg30d=-18.18% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.17 | Chg30d=-222.22% | Revisions=-25% | GrowthEPS=-212.6% | GrowthRev=+5.4%
EPS next Year (2027-12-31): EPS=0.38 | Chg30d=-26.21% | Revisions=-25% | GrowthEPS=+330.3% | GrowthRev=+17.8%
[Analyst] Revisions Ratio: -50% (up=0, down=3)